Genmab — Maj 2017
-
God morgen.
-
Ny forskningschef fremlægger BMS’ comeback-strategi
Bristol-Myers Squibbs nye F&U-direktør har en klar plan for, hvordan man skal komme tilbage på sporet med sin forskning og udvikling af særligt immunonkologiske midler. Kodeordet er blandt andet kombinationer.
(medwatch.dk)
-
-
-
Desværre er der nok ikke det vilde at hente for Genmab - her er hvad der står i den oprindelige aftale:Copenhagen, Denmark; May 30, 2012 — Genmab A/S (OMX: GEN) announced today it has granted an exclusive, worldwide license to its HuMax
-IL8 antibody to Cormorant Pharmaceuticals. Under the terms of the agreement, Genmab will receive an upfront payment and will be entitled to milestone payments and royalties on net sales. Cormorant intends to evaluate HuMax-IL8 for treatment of select cancers a -
Der er sandt for dyden ikke mange nyheder at sætte tænderne i, når man ser bort fra dara. De næste IND'er ser ud til først at komme i Q4
-
Er der i øvrigt nogen forklaring på, hvorfor det tager så lang tid at få cd20/cd3 i klinikken? Det koncept er da ældre end metusalem...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind